INGRIDA PAKALNISKYTE: Open Payments
NPI 1598836371 · LINCOLN, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$674 in 34 payments from 20 companies in 2025. Trend: 2023 $145 · 2024 $335 · 2025 $674
Food & beverage: $674
| Company | Payments | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC | 4 | $73 |
| Novartis Pharmaceuticals Corporation | 1 | $65 |
| BeOne Medicines USA, Inc. | 3 | $52 |
| GlaxoSmithKline, LLC. | 3 | $49 |
| Genentech USA, Inc. | 2 | $48 |
| SERVIER PHARMACEUTICALS LLC | 2 | $45 |
| Daiichi Sankyo Inc. | 2 | $39 |
| AstraZeneca Pharmaceuticals LP | 2 | $39 |
| Janssen Biotech, Inc. | 2 | $37 |
| ABBVIE INC. | 2 | $35 |
Products named: KEYTRUDA, KISQALI, Enhertu, RYBREVANT, TEVIMBRA, JEMPERLI, VERZENIO, Polivy.
Industry payments across NE — which companies pay providers there.
